Kiora Pharmaceuticals Reports KIO-300 Suppresses Seizure Activity in Preclinical Epilepsy Model

Kiora Pharmaceuticals announced that its ion channel modulator KIO-300 significantly reduced epileptiform activity in an ex vivo temporal lobe epileps...